StockNews.AI
NBTX
StockNews.AI
141 days

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

1. NBTX to report Q4 and full year 2024 financial results on April 2. 2. Conference call scheduled for April 3 at 8 AM EDT for updates. 3. CEO Laurent Levy will discuss year-end results and business activities. 4. Nanobiotix focuses on nanoparticle-based cancer treatments. 5. Company holds over 25 patents related to its technology platforms.

4m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report may provide mixed signals about NBTX's financial health, similar to past reports which influenced volatility but no strong trends were established.

How important is it?

The upcoming earnings report is significant but speculative, with potential for varied investor reactions. Past earnings announcements showed potential for short-term fluctuations, warranting cautious attention.

Why Short Term?

The earnings report will drive immediate market reactions, reminiscent of previous earnings that affected stock price volatility temporarily.

Related Companies

NANO
PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, on Wednesday, April 2, 2025, after the close of the U.S. market. This release will be followed by a conference call and webcast on Thursday, April 3, 2025, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial and business officer, will briefly review the Company’s year-end results and provide an update on business activities for the fourth quarter and full year of 2024 before taking questions from participants. Details of the call are as follows: Webcast link: click here        Conference call link: click here Details of the call are also available in the investors section of the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior the event start. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website. Participants are invited to email their questions in advance to investors@nanobiotix.com. About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter. Contacts Nanobiotix Communications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835contact@nanobiotix.comInvestor Relations DepartmentCraig WestSVP, Investor Relations+1 (617) 583-0211Investors@nanobiotix.com  Media Relations France – HARDYCaroline Hardy+33 06 70 33 49 50carolinehardy@outlook.frGlobal – uncapped Communicationsnanobiotixteam@uncappedcommunications.com  2025-03-31 -- NBTX -- 4Q & FY24 STD -- FINAL.pdf

Related News